A Phase Ib/II Open-Label Study of the Safety Tolerability and Efficacy of Trastuzumab-MCC-DM1 in Combination with Pertuzumab Administered Intravenously to Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Progressed Whil
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
18 years - 100 years
All
Phase
N/A
1 Location
Brief description of study
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Breast Cancer
-
Age: 18 years - 100 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1011004174 (0903-19)
